CHAPTER 1. METHODOLOGY AND SCOPE
1.1. MARKET SEGMENTATION & SCOPE
1.2. SEGMENT DEFINITIONS
1.2.1. DRUG TYPE
1.2.2. ALLERGEN TYPE
1.2.3. END USE
1.2.4. REGIONAL SCOPE
1.2.5. ESTIMATES AND FORECASTS TIMELINE
1.3. RESEARCH METHODOLOGY
1.4. INFORMATION PROCUREMENT
1.4.1. PURCHASED DATABASE
1.4.2. GVR’S INTERNAL DATABASE
1.4.3. SECONDARY SOURCES
1.4.4. PRIMARY RESEARCH
1.4.5. DETAILS OF PRIMARY RESEARCH
1.4.5.1. DATA FOR PRIMARY INTERVIEWS IN NORTH AMERICA
1.4.5.2. DATA FOR PRIMARY INTERVIEWS IN EUROPE
1.4.5.3. DATA FOR PRIMARY INTERVIEWS IN ASIA PACIFIC
1.4.5.4. DATA FOR PRIMARY INTERVIEWS IN LATIN AMERICA
1.4.5.5. DATA FOR PRIMARY INTERVIEWS IN MEA
1.5. INFORMATION OR DATA ANALYSIS
1.5.1. DATA ANALYSIS MODELS
1.6. MARKET FORMULATION & VALIDATION
1.7. MODEL DETAILS
1.7.1. COMMODITY FLOW ANALYSIS (MODEL 1)
1.7.2. APPROACH 1: COMMODITY FLOW APPROACH
1.7.3. VOLUME PRICE ANALYSIS (MODEL 2)
1.7.4. APPROACH 2: VOLUME PRICE ANALYSIS
1.8. LIST OF SECONDARY SOURCES
1.9. LIST OF PRIMARY SOURCES
1.10. OBJECTIVES
CHAPTER 2. EXECUTIVE SUMMARY
2.1. MARKET OUTLOOK
2.2. SEGMENT OUTLOOK
2.3. COMPETITIVE INSIGHTS
CHAPTER 3. FOOD ALLERGY TREATMENT MARKET VARIABLES, TRENDS & SCOPE
3.1. MARKET LINEAGE OUTLOOK
3.1.1. PARENT MARKET OUTLOOK
3.1.2. RELATED/ANCILLARY MARKET OUTLOOK
3.2. MARKET DYNAMICS
3.2.1. MARKET DRIVER ANALYSIS
3.2.1.1. INCREASING PREVALENCE OF PEANUT ALLERGY
3.2.1.2. INCREASING FUNDING FOR NOVEL DRUG DISCOVERY
3.2.1.3. RISING AWARENESS PROGRAMS
3.2.2. MARKET RESTRAINT ANALYSIS
3.2.2.1. HIGH COST OF TREATMENT AND PRODUCTS
3.3. FOOD ALLERGY TREATMENT MARKET ANALYSIS TOOLS
3.3.1. INDUSTRY ANALYSIS – PORTER’S
3.3.1.1. SUPPLIER POWER
3.3.1.2. BUYER POWER
3.3.1.3. SUBSTITUTION THREAT
3.3.1.4. THREAT OF NEW ENTRANT
3.3.1.5. COMPETITIVE RIVALRY
3.3.2. PESTEL ANALYSIS
3.3.2.1. POLITICAL LANDSCAPE
3.3.2.2. TECHNOLOGICAL LANDSCAPE
3.3.2.3. ECONOMIC LANDSCAPE
3.3.3. PRICING ANALYSIS
CHAPTER 4. FOOD ALLERGY TREATMENT MARKET: BY ALLERGEN TYPE ESTIMATES & TREND ANALYSIS
4.1. SEGMENT DASHBOARD
4.2. GLOBAL FOOD ALLERGY TREATMENT MARKET BY ALLERGEN TYPE OUTLOOK
4.3. GLOBAL FOOD ALLERGY TREATMENT MARKET SIZE & TREND ANALYSIS, BY ALLERGEN TYPE, 2025 TO 2033
4.4. PEANUTS
4.4.1. MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
4.5. TREE NUTS
4.5.1. MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
4.6. TREE NUTS
4.6.1. MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
4.7. DAIRY PRODUCTS
4.7.1. MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
4.8. POULTRY PRODUCT
4.8.1. MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
4.9. SHELLFISH
4.9.1. MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
4.10. WHEAT
4.10.1. MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
4.11. SOYS
4.11.1. MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
4.12. OTHER
4.12.1. MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
CHAPTER 5. FOOD ALLERGY TREATMENT MARKET: BY DRUG TYPE ESTIMATES & TREND ANALYSIS
5.1. SEGMENT DASHBOARD
5.2. GLOBAL FOOD ALLERGY TREATMENT MARKET DRUG TYPE MOVEMENT ANALYSIS
5.3. GLOBAL FOOD ALLERGY TREATMENT MARKET SIZE & TREND ANALYSIS, BY DRUG TYPE, 2025 TO 2033
5.4. EPINEPHRINE
5.4.1. MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
5.5. EPINEPHRINE
5.5.1. MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
5.6. IMMUNOTHERAPY
5.6.1. MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
5.6.2. XOLAIR
5.6.2.1. MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
5.6.3. PALFORZIA
5.6.3.1. MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
5.6.4. OTHERS
5.6.4.1. MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
5.7. ANTIHISTAMINES
CHAPTER 6. FOOD ALLERGY TREATMENT MARKET: BY ROUTE OF ADMINISTRATION ESTIMATES & TREND ANALYSIS
6.1. SEGMENT DASHBOARD
6.2. GLOBAL FOOD ALLERGY TREATMENT MARKET MOVEMENT ANALYSIS
6.3. GLOBAL FOOD ALLERGY TREATMENT MARKET SIZE & TREND ANALYSIS, BY ROUTE OF ADMINISTRATION, 2025 TO 2033
6.4. ORAL
6.4.1. MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
6.5. PARENTERAL
6.5.1. MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
6.6. OTHER
6.6.1. MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
CHAPTER 7. FOOD ALLERGY TREATMENT MARKET: BY END USE ESTIMATES & TREND ANALYSIS
7.1. SEGMENT DASHBOARD
7.2. GLOBAL FOOD ALLERGY TREATMENT MARKET MOVEMENT ANALYSIS
7.3. GLOBAL FOOD ALLERGY TREATMENT MARKET SIZE & TREND ANALYSIS, BY END USE 2025 TO 2033
7.4. HOSPITAL PHARMACIES
7.4.1. MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
7.5. RETAIL PHARMACIES
7.5.1. MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
7.6. OTHERS
7.6.1. MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
CHAPTER 8. FOOD ALLERGY TREATMENT MARKET: REGIONAL ESTIMATES & TREND ANALYSIS BY
8.1. REGIONAL MARKET DASHBOARD
8.2. MARKET SIZE, & FORECASTS TREND ANALYSIS, 2018 TO 2030:
8.3. NORTH AMERICA
8.3.1. U.S.
8.3.1.1. KEY COUNTRY DYNAMICS
8.3.1.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
8.3.1.3. COMPETITIVE SCENARIO
8.3.1.4. U.S. MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
8.3.2. CANADA
8.3.2.1. KEY COUNTRY DYNAMICS
8.3.2.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
8.3.2.3. COMPETITIVE SCENARIO
8.3.2.4. CANADA MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
8.3.3. MEXICO
8.3.3.1. KEY COUNTRY DYNAMICS
8.3.3.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
8.3.3.3. COMPETITIVE SCENARIO
8.3.3.4. MEXICO MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
8.4. EUROPE
8.4.1. UK
8.4.1.1. KEY COUNTRY DYNAMICS
8.4.1.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
8.4.1.3. COMPETITIVE SCENARIO
8.4.1.4. UK MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
8.4.2. GERMANY
8.4.2.1. KEY COUNTRY DYNAMICS
8.4.2.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
8.4.2.3. COMPETITIVE SCENARIO
8.4.2.4. GERMANY MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
8.4.3. FRANCE
8.4.3.1. KEY COUNTRY DYNAMICS
8.4.3.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
8.4.3.3. COMPETITIVE SCENARIO
8.4.3.4. FRANCE MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
8.4.4. ITALY
8.4.4.1. KEY COUNTRY DYNAMICS
8.4.4.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
8.4.4.3. COMPETITIVE SCENARIO
8.4.4.4. ITALY MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
8.4.5. SPAIN
8.4.5.1. KEY COUNTRY DYNAMICS
8.4.5.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
8.4.5.3. COMPETITIVE SCENARIO
8.4.5.4. SPAIN MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
8.4.6. NORWAY
8.4.6.1. KEY COUNTRY DYNAMICS
8.4.6.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
8.4.6.3. COMPETITIVE SCENARIO
8.4.6.4. NORWAY MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
8.4.7. SWEDEN
8.4.7.1. KEY COUNTRY DYNAMICS
8.4.7.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
8.4.7.3. COMPETITIVE SCENARIO
8.4.7.4. SWEDEN MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
8.4.8. DENMARK
8.4.8.1. KEY COUNTRY DYNAMICS
8.4.8.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
8.4.8.3. COMPETITIVE SCENARIO
8.4.8.4. DENMARK MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
8.5. ASIA PACIFIC
8.5.1. JAPAN
8.5.1.1. KEY COUNTRY DYNAMICS
8.5.1.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
8.5.1.3. COMPETITIVE SCENARIO
8.5.1.4. JAPAN MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
8.5.2. CHINA
8.5.2.1. KEY COUNTRY DYNAMICS
8.5.2.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
8.5.2.3. COMPETITIVE SCENARIO
8.5.2.4. CHINA MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
8.5.3. INDIA
8.5.3.1. KEY COUNTRY DYNAMICS
8.5.3.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
8.5.3.3. COMPETITIVE SCENARIO
8.5.3.4. INDIA MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
8.5.4. AUSTRALIA
8.5.4.1. KEY COUNTRY DYNAMICS
8.5.4.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
8.5.4.3. COMPETITIVE SCENARIO
8.5.4.4. AUSTRALIA MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
8.5.5. SOUTH KOREA
8.5.5.1. KEY COUNTRY DYNAMICS
8.5.5.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
8.5.5.3. COMPETITIVE SCENARIO
8.5.5.4. SOUTH KOREA MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
8.5.6. THAILAND
8.5.6.1. KEY COUNTRY DYNAMICS
8.5.6.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
8.5.6.3. COMPETITIVE SCENARIO
8.5.6.4. THAILAND MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
8.6. LATIN AMERICA
8.6.1. BRAZIL
8.6.1.1. KEY COUNTRY DYNAMICS
8.6.1.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
8.6.1.3. COMPETITIVE SCENARIO
8.6.1.4. BRAZIL MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
8.6.2. ARGENTINA
8.6.2.1. KEY COUNTRY DYNAMICS
8.6.2.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
8.6.2.3. COMPETITIVE SCENARIO
8.6.2.4. ARGENTINA MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
8.7. MEA
8.7.1. SOUTH AFRICA
8.7.1.1. KEY COUNTRY DYNAMICS
8.7.1.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
8.7.1.3. COMPETITIVE SCENARIO
8.7.1.4. SOUTH AFRICA MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
8.7.2. SAUDI ARABIA
8.7.2.1. KEY COUNTRY DYNAMICS
8.7.2.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
8.7.2.3. COMPETITIVE SCENARIO
8.7.2.4. SAUDI ARABIA MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
8.7.3. UAE
8.7.3.1. KEY COUNTRY DYNAMICS
8.7.3.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
8.7.3.3. COMPETITIVE SCENARIO
8.7.3.4. UAE MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
8.7.4. KUWAIT
8.7.4.1. KEY COUNTRY DYNAMICS
8.7.4.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
8.7.4.3. COMPETITIVE SCENARIO
8.7.4.4. KUWAIT MARKET ESTIMATES AND FORECASTS, 2025 TO 2033
CHAPTER 9. COMPETITIVE LANDSCAPE
9.1. RECENT DEVELOPMENTS & IMPACT ANALYSIS, BY KEY MARKET PARTICIPANTS
9.2. COMPANY/COMPETITION CATEGORIZATION
9.3. VENDOR LANDSCAPE
9.3.1. LIST OF KEY DISTRIBUTORS AND CHANNEL PARTNERS
9.3.2. KEY CUSTOMERS
9.3.3. KEY COMPANY MARKET SHARE ANALYSIS, 2024
9.3.4. ALERJE, INC.
9.3.4.1. COMPANY OVERVIEW
9.3.4.2. FINANCIAL PERFORMANCE
9.3.4.3. PRODUCT BENCHMARKING
9.3.4.4. STRATEGIC INITIATIVES
9.3.5. CAMALLERGY
9.3.5.1. COMPANY OVERVIEW
9.3.5.2. FINANCIAL PERFORMANCE
9.3.5.3. PRODUCT BENCHMARKING
9.3.5.4. STRATEGIC INITIATIVES
9.3.6. COUR PHARMACEUTICALS DEVELOPMENT COMPANY, INC.
9.3.6.1. COMPANY OVERVIEW
9.3.6.2. FINANCIAL PERFORMANCE
9.3.6.3. PRODUCT BENCHMARKING
9.3.6.4. STRATEGIC INITIATIVES
9.3.7. DBV TECHNOLOGIES
9.3.7.1. COMPANY OVERVIEW
9.3.7.2. FINANCIAL PERFORMANCE
9.3.7.3. PRODUCT BENCHMARKING
9.3.7.4. STRATEGIC INITIATIVES
9.3.8. GENENTECH
9.3.8.1. COMPANY OVERVIEW
9.3.8.2. FINANCIAL PERFORMANCE
9.3.8.3. PRODUCT BENCHMARKING
9.3.8.4. STRATEGIC INITIATIVES
9.3.9. HAL ALLERGY
9.3.9.1. COMPANY OVERVIEW
9.3.9.2. FINANCIAL PERFORMANCE
9.3.9.3. PRODUCT BENCHMARKING
9.3.9.4. STRATEGIC INITIATIVES
9.3.10. INIMMUNE CORPORATION
9.3.10.1. COMPANY OVERVIEW
9.3.10.2. FINANCIAL PERFORMANCE
9.3.10.3. PRODUCT BENCHMARKING
9.3.10.4. STRATEGIC INITIATIVES
9.3.11. INTROMMUNE THERAPEUTICS
9.3.11.1. COMPANY OVERVIEW
9.3.11.2. FINANCIAL PERFORMANCE
9.3.11.3. PRODUCT BENCHMARKING
9.3.11.4. STRATEGIC INITIATIVES
9.3.12. NEMAGEN DISCOVERIES
9.3.12.1. COMPANY OVERVIEW
9.3.12.2. FINANCIAL PERFORMANCE
9.3.12.3. PRODUCT BENCHMARKING
9.3.12.4. STRATEGIC INITIATIVES
9.3.13. PROTA THERAPEUTICS PTY. LTD.
9.3.13.1. COMPANY OVERVIEW
9.3.13.2. FINANCIAL PERFORMANCE
9.3.13.3. PRODUCT BENCHMARKING
9.3.13.4. STRATEGIC INITIATIVES
9.3.14. SIOLTA THERAPEUTICS
9.3.14.1. COMPANY OVERVIEW
9.3.14.2. FINANCIAL PERFORMANCE
9.3.14.3. PRODUCT BENCHMARKING
9.3.14.4. STRATEGIC INITIATIVES
9.3.15. STALLERGENES GREER
9.3.15.1. COMPANY OVERVIEW
9.3.15.2. FINANCIAL PERFORMANCE
9.3.15.3. PRODUCT BENCHMARKING
9.3.15.4. STRATEGIC INITIATIVES
9.3.16. VEDANTA BIOSCIENCES
9.3.16.1. COMPANY OVERVIEW
9.3.16.2. FINANCIAL PERFORMANCE
9.3.16.3. PRODUCT BENCHMARKING
9.3.16.4. STRATEGIC INITIATIVES
9.3.17. OTHERS
9.3.17.1. COMPANY OVERVIEW
9.3.17.2. FINANCIAL PERFORMANCE
9.3.17.3. PRODUCT BENCHMARKING
9.3.17.4. STRATEGIC INITIATIVES
CHAPTER 10. CONCLUSION
著作権 ©2022 無断複写・転載を禁じます
